Principia Biopharma (PRNB) Earns Outperform Rating from Analysts at Wells Fargo & Co
Wells Fargo & Co initiated coverage on shares of Principia Biopharma (NASDAQ:PRNB) in a report issued on Tuesday, Marketbeat Ratings reports. The firm issued an outperform rating on the stock.
Separately, Bank of America began coverage on shares of Principia Biopharma in a research note on Tuesday. They issued a buy rating on the stock.
Shares of NASDAQ:PRNB opened at $25.09 on Tuesday. Principia Biopharma has a 12 month low of $23.95 and a 12 month high of $36.00.
Principia Biopharma Company Profile
Principia Biopharma Inc, a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome.
Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.